Seed portfolio

Noninvasive Implantation Capability Screening (NICS®)

Optimization for the embryo selection and implantation priority

I am a doctor

Why Noninvasive Implantation Capability Screening (NICS®)?


Preimplantation genetic testing for aneuploidy (PGT-A) with trophectoderm (TE) biopsy is widely applied in in vitro fertilization (IVF) to identify aneuploidy embryos. However, biopsy may reduce the embryo viability.


Potential safety regarding biopsy is still unknown for long-term, and needs sustained attention.


NICS® technology uses blastocyst culture fluid as sample instead of embryo biopsy, thus no additional impact on embryo, nor unknown long-term health effects.

For who?

1 Biopsy of patients with no transplantable embryos (PGT-A without euploid embryos)

2 Patients with low-grade embryos requiring chromosomal screening (embryos not suitable for biopsy for PGT-A)

3 Elderly patients (>35 years old)

4 Patients with ≥2 implantation failures/miscarriages

Service Process